Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda Pharmaceutical sees profits rise 11 per cent in first half

Takeda Pharmaceutical sees profits rise 11 per cent in first half

4th November 2005

Japanese drugmaker Takeda Pharmaceutical has announced its first half results, which showed the company boosted profits by 11 per cent on a net income of 181.3 billion yen ($1.5 billion).

Domestic sales of its Actos diabetes treatment and Blopress blood pressure drug were largely credited with producing the promising results from the Osaka based firm.

The company raised its annual profit forecast for the year to March 2006, projecting 310 billion yen net income, compared with its 295 billion yen estimate in July.

Sales were forecast at 1.195 trillion yen, compared with 1.155 trillion yen in July.

Sales of Actos, Takeda’s primary profit generator, rose 20 per cent worldwide from a year earlier to 111.5 billion yen, and were boosted by the results of a four-year study published in September that showed the drug reduced heart attacks and strokes by 16 per cent in patients already taking heart medications.

Global sales of Blopress rose 24 per cent to 93.2 billion yen while worldwide Takepron sales fell 8.4 per cent to 193.2 billion yen.

The company said it plans to spend about 30 per cent of its profit to pay a dividend of 106 yen a share for the year ending March 2006. Takeda shares rose 70 yen, or 1.1 per cent, to 6,510 yen at the close of Japanese trading yesterday.

track© Adfero Ltd

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.